Benzodiazepine use in schizophrenia
I read with interest the paper by Mehta et al. (2017) addressing the issue of eszopiclone use for negative symptoms in schizophrenia as it points out to the novel therapeutic targets. Authors report on eszopiclone use in add-on therapy to antipsychotics being efficacious for persistent deficit symptoms in schizophrenia treatment including cognitive decline. Non-benzodiazepine hypnotic drugs produce its hypnotic effects via the GABA-A benzodiazepine receptor complex sharing pharmacodynamics with benzodiazepines, in particular, in higher doses (Cuba ła and Landowski, 2007). (Source: Schizophrenia Research)
Source: Schizophrenia Research - September 25, 2017 Category: Psychiatry Authors: Adam W łodarczyk Tags: Letter to the Editor Source Type: research
Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities
ConclusionsHere, we provided a tentative guide for the use of drugs for insomnia in children with NDDs. Well‐controlled studies employing both objective polysomnography and subjective sleep measures are needed to determine the efficacy, effectiveness, and safety of the currently prescribed pediatric sleep medicines in children with NDDs. (Source: Journal of Child Psychology and Psychiatry)
Source: Journal of Child Psychology and Psychiatry - September 18, 2017 Category: Psychiatry Authors: Oliviero Bruni, Marco Angriman, Fabrizio Calisti, Alessandro Comandini, Giovanna Esposito, Samuele Cortese, Raffaele Ferri Tags: Practitioner Review Source Type: research
Insomnia: Pharmacologic Therapy.
Abstract
Insomnia accounts for more than 5.5 million visits to family physicians each year. Although behavioral interventions are the mainstay of treatment, pharmacologic therapy may be necessary for some patients. Understanding the risks and benefits of insomnia medications is critical. Controlled-release melatonin and doxepin are recommended as first-line agents in older adults; the so-called z-drugs (zolpidem, eszopiclone, and zaleplon) should be reserved for use if the first-line agents are ineffective. For the general population with difficulty falling asleep, controlled-release melatonin and the z-dr...
Source: American Family Physician - July 1, 2017 Category: Primary Care Authors: Matheson E, Hainer BL Tags: Am Fam Physician Source Type: research
Eszopiclone for persistent negative symptoms in schizophrenia – An unintended N-of-1 study
In this report we highlight the potential utility of eszopiclone in treating persistent negative symptoms in a patient with chronic schizophrenia. (Source: Schizophrenia Research)
Source: Schizophrenia Research - June 21, 2017 Category: Psychiatry Authors: Urvakhsh Meherwan Mehta, Vinutha Ravishankar, Jagadisha Thirthalli Source Type: research
GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.
Abstract
GABAA receptor positive allosteric modulators (GABAA receptor modulators) are commonly used for the treatment of insomnia. Nevertheless, the effects of these compounds on psychostimulant-induced sleep impairment are poorly understood. Because GABAA receptor modulators have been shown to decrease the abuse-related effects of psychostimulants, the aim of the present study was to evaluate the effects of temazepam (0.3, 1.0 or 3.0 mg/kg) and eszopiclone (0.3, 1.0 or 3.0 mg/kg), two GABAA receptor modulators, on the behavioral neuropharmacology of methamphetamine in adult rhesus macaques (n = 5). S...
Source: Neuropharmacology - May 8, 2017 Category: Drugs & Pharmacology Authors: Berro LF, Andersen ML, Tufik S, Howell LL Tags: Neuropharmacology Source Type: research
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem ‐containing medications
ConclusionThe DSCs related to zolpidem‐containing products shifted prescribing toward the lower‐dose formulations, consistent with the recommendations in the DSCs. Copyright © 2017 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - April 27, 2017 Category: Drugs & Pharmacology Authors: Aaron S. Kesselheim, Macarius Donneyong, Gerald J. Dal Pan, Esther H. Zhou, Jerry Avorn, Sebastian Schneeweiss, John D. Seeger Tags: Original Report Source Type: research
The dual orexin receptor antagonist, DORA ‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine
This article is protected by copyright. All rights reserved. (Source: Journal of Neurochemistry)
Source: Journal of Neurochemistry - April 26, 2017 Category: Neuroscience Authors: Lihang (Leon) Yao, Andres Ramirez, Anthony J. Roecker, Steven Fox, Jason Uslaner, Sean M. Smith, Robert Hodgson, Paul J. Coleman, John J. Renger, Christopher J. Winrow, Anthony L. Gotter Tags: Original Article Source Type: research
Response to a combination of oxygen and a hypnotic as treatment for obstructive sleep apnoea is predicted by a patient's therapeutic CPAP requirement
ConclusionTherapeutic CPAP requirement, as a surrogate measure of pharyngeal collapsibility, predicts the response to non‐anatomical therapy (oxygen and eszopiclone) for OSA. (Source: Respirology)
Source: Respirology - April 14, 2017 Category: Respiratory Medicine Authors: Shane A. Landry, Simon A. Joosten, Scott A. Sands, David P. White, Atul Malhotra, Andrew Wellman, Garun S. Hamilton, Bradley A. Edwards Tags: Original Article Source Type: research
Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment
ConclusionThere is generally poor evidence for prescribing drugs for behavioural insomnia in children with ADHD. Further controlled studies are warranted. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 8, 2017 Category: Pediatrics Source Type: research
Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.
CONCLUSION: There is generally poor evidence for prescribing drugs for behavioural insomnia in children with ADHD. Further controlled studies are warranted.
PMID: 28391425 [PubMed - as supplied by publisher] (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2017 Category: Pediatrics Authors: Anand S, Tong H, Besag FM, Chan EW, Cortese S, Wong IC Tags: Paediatr Drugs Source Type: research
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study
ConclusionsSome risks of medications are effectively communicated to patients and physicians; however, there is still a noticeable gap between information issued by the Food and Drug Administration and patient and physician awareness of this knowledge, as well as patients ’ decisions to act on this information. Disseminators of emerging drug safety information should explore ways of providing user-friendly resources to patients and healthcare professionals that can update them on new risks in a timely manner. (Source: Drug Safety)
Source: Drug Safety - February 27, 2017 Category: Drugs & Pharmacology Source Type: research
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline
Introduction:The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of ...
Source: Journal of Clinical Sleep Medicine : JCSM - February 15, 2017 Category: Sleep Medicine Source Type: research
Eszopiclone and Zolpidem Do Not Affect the Prevalence of the Low Arousal Threshold Phenotype
Conclusions:The LAT is common in our population and NBSH premedication does not alter its occurrence. Further studies are needed to determine how the LAT can be optimally managed to improve OSA treatment.Citation:Smith PR, Sheikh KL, Costan-Toth C, Forsthoefel D, Bridges E, Andrada TF, Holley AB. Eszopiclone and zolpidem do not affect the prevalence of the low arousal threshold phenotype.J Clin Sleep Med. 2017;13(1):115–119. (Source: Journal of Clinical Sleep Medicine : JCSM)
Source: Journal of Clinical Sleep Medicine : JCSM - January 14, 2017 Category: Sleep Medicine Source Type: research
An update of management of insomnia in patients with chronic orofacial pain
This article is protected by copyright. All rights reserved. (Source: Oral Diseases)
Source: Oral Diseases - December 31, 2016 Category: ENT & OMF Authors: Galit Almoznino, Yaron Haviv, Yair Sharav, Rafael Benoliel Tags: Review Article Source Type: research
